INTRODUCTION
============

The attention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder (worldwide prevalence, 5.29%)[@b1-cpn-17-446] and is defined by persistent symptoms of inattention, hyperactivity and impulsivity. It is commonly diagnosed in childhood but could persist into adulthood with a margin that exceeds 60%.[@b2-cpn-17-446] For this psychiatric disease, methylphenidate (MPH) is the main psychostimulant drug prescribed to children and adolescents.[@b3-cpn-17-446] It acts by blocking the dopamine and noradrenaline transporters.[@b4-cpn-17-446]

Some studies demonstrated that dopamine has an important role in the prepubertal maturation stages and early exposure to MPH could lead to long-lasting alterations in brain dopamine pathways and natural reward systems[@b5-cpn-17-446],[@b6-cpn-17-446] which are related to sexual behavior performance, alterations on hormonal profile and also with the negative effect on appetite and body mass index (BMI), delayed puberty.[@b7-cpn-17-446],[@b8-cpn-17-446]

In this brief report, we will discuss the possible effects and underpinning mechanisms of MPH on an unexpected side effect (precocious pubertal development, PPD) of seven children who had a normal BMI.

CASE
====

Children were treated with MPH (0.5 mg/kg/dose three times a day, maximum 60 mg) at least for 6 months (6--12 months). Anthropometric evaluation, and endocrinological investigation were performed to all children at Department of Pediatric Endocrinology, Ufuk University in Ankara, Turkey. In this investigation, the pubertal development stages were assessed according to Marshall and Tanner scale and the bone age was assessed using the Greulich and Pyle atlas. PPD was diagnosed if the breast development started before the age of 8 years or menarche started before the age of 10 years in girls or and testis volumes were \> 3 ml before the age of 9 years in boys. Pelvic ultrasound, neuroradiological imaging and evaluation of the hypothalamic-pituitary-gonadal axis (HPGA) by measuring basal and stimulated luteinizing hormone (LH) and follicle stimulating hormone (FSH) peaks, and the plasma concentration of estradiol or testosterone were performed. Gonadotropin hormones were measured using the immunochemiluminometric method. Children were followed for at least 6 months after the diagnosis of PPD. MPH treatment was not ceased during follow-up. Anthropometric and pubertal evaluation, serum LH, FSH, estradiol or testosterone levels and pelvic ultra-sonography was performed trimonthly. Written informed consent was obtained from the patients and their parents.

The mean age of the seven children (4 girls, 3 boys) was 8.16 years. Basal hormonal levels (LH, thyrotrophin stimulating hormone, estrogen/testosterone) were within normal range. LH-releasing hormone (LHRH) stimulation test was performed to all of the cases and results of the tests demonstrated central pubertal responses. Children all had normal range of brain magnetic resonance imaging (MRI). [Table 1](#t1-cpn-17-446){ref-type="table"} shows the hormonal profiles, somatic progress, and prognosis of the children in detailed form. One child (Case 1) was put on gonadotropin-releasing hormone (GnRH) analog treatment since she developed rapidly progressing PPD. Pubertal stage of the other cases didn't progress during 6 months interval.

DISCUSSION
==========

Studies showed that ADHD is a complex neuro-psychiatric disorder in which dopamine and noradrenaline systems of the brain affected.[@b9-cpn-17-446] The prefrontal cortex, orbitofrontal cortex, and basal ganglions are the dopamine-rich regions of the brain and functional MRI studies show that the cases with ADHD have decreased activity in prefrontal cortex and basal ganglions.[@b10-cpn-17-446] MPH increases dopamine and noradrenaline level in the synaptic gap by the inhibition of the dopamine and noradrenaline transporters in these regions and reduce the symptoms.

PPD is a consequence of decreased activity of central suppressor system on GnRH neurons and the increased activity of the prominence excitatory systems. Glutamine, dopamine, and noradrenaline are the most important excitatory neurotransmitters that have a role in starting puberty.[@b11-cpn-17-446] The effect of MPH, cumulating dopamine and noradrenaline in the synaptic gap, may induce puberty by affecting their own receptors. There are some animal study evidences that confirm this hypothesis; in the study of Adriani *et al*.,[@b12-cpn-17-446] 2 mg/kg/day MPH and saline have been injected on 30 to 44 days old rats. They observed that in the MPH injected group, weight of testicles and amount of sperm have increased and these findings interpreted as subchronic MPH exposure in adolescent rats could have a trophic action on testis growth and a negative impact on testosterone metabolism. Davison and Kuenzel[@b13-cpn-17-446] damaged the part of the lateral hypothalamus of 2 weeks old special chicken and observed increment of chicken testicles in size. They detected increased amount of hypothalamic biologic amines and dopamine in eminentia media. They related the enlargement of testicles with increased amount of dopamine, which has an excitatory effect on gonadotrophin release. Chatterjee-Chakrabarty *et al*.[@b14-cpn-17-446] examined the effects of long-term MPH in the reproductive axis of adolescent female rats by comparing the results with drug-naive ones. They determined high level of LH in hypophysis and histologically premature luteinize ovarian follicles in the MPH group. The data about unexpected effects of MPH on reproductive system of children are extremely rare. Kelly *et al*.[@b15-cpn-17-446] reported a 12 years old prepubertal boy with recurrent erections who had been on MPH treatment for 2 years. In another case report, 7 years old girl with ADHD developed excessive hypersexual masturbation and behavior during MPH treatment.[@b16-cpn-17-446] Coskun and Zoroglu[@b17-cpn-17-446] reported 8 years old and 15 years old two boys who developed hypersexual behaviors and recurrent erections during MPH treatment. In one case report hypersexual behaviors and PPD are identified in children and adolescents due to clonidine treatment for ADHD, which is a noradrenaline receptor agonist.[@b18-cpn-17-446] On the other hand dopamine agonists show anti-prolactinergic effect with hypophyseal D2 receptor stimulation and studies showed that prolactin suppresses GnRH receptor expression in both hypophysis and hypothalamus.[@b9-cpn-17-446]

As conclusion, using psychostimulant drugs at childhood may accelerate puberty with the excitatory effect of dopamine's and noradrenaline's GnRH release and with the disappearance of GnRH receptor expression suppressor effect on prolactin's HPGA region with prolactin disinhibitory effect. In this case series, the story of PPD in MPH treated children with high/normal BMI is quite remarkable. Eventually, the facts discussed in the literature bring to mind a question: Could LHRH agonist treatment be effective when MPH and other drugs with similar mechanisms causing PPD? Even though the animal studies support our hypothesis, this possible side effect and LHRH treatment must be investigated in big samples of children and adolescents. According to these results, children who get MPH and have normal or high BMI should be evaluated more carefully for PPD during treatment.

This study was presented as a poster in ENDO 2016, 98th Annual Meeting and Expo of the Endocrine Society, 1--4 April 2016, Boston, MA, USA.
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Anthropometric and endocrinological evaluations all of the cases

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                          Case 1                                  Case 2                                         Case 3               Case 4               Case 5                                         Case 6                        Case 7
  --------------------------------------- --------------------------------------- ---------------------------------------------- -------------------- -------------------- ---------------------------------------------- ----------------------------- ----------------------------------------------
  Age                                     7 yr 11 mo                              7 yr 6 mo                                      8 yr 2 mo            7 yr 9 mo            8 yr 6 mo                                      8 yr 10 mo                    8 yr 6 mo

  Complaint                               Breast development                      Breast development                             Breast development   Breast development   Macroorchidism                                 Macroorchidism                Macroorchidism

  Duration of complaints (mo)             4                                       3                                              5                    2                    6                                              4                             3

  Family history                          ADHD                                    ADHD                                           ADHD                 ADHD                 ADHD                                           ADHD                          ADHD

  Use of drug/duration                    MPH/12 mo                               MPH/10 mo                                      MPH/8 mo             MPH/9 mo             MPH/9 mo                                       MPH/9 mo                      MPH/6 mo

  Weight percentile                       \> 97                                   75--90                                         \> 97                90--97               75                                             50                            90

  Height percentile                       75--90                                  25                                             90--97               50--75               50                                             50                            25--50

  Thelarche                               Bilateral T2                            RightT3/left T2                                Bilateral T3         RightT3/Left T2                                                                                   

  Testis volumes (ml)                                                                                                                                                      3/4                                            3/4                           4/4

  Penile stretched length (percentiles)                                                                                                                                    50--75                                         75--90                        75--90

  Bone age                                9 yr                                    9 yr                                           10 yr 6 mo           10 yr                9 yr                                           14.5 yr                       14.5 yr

  E2 (pg/ml)                              13                                      18                                             44                   16                   \-                                             \-                            \-

  Testosterone (ng/ml)                    \-                                      \-                                             \-                                        2.30                                           6.95                          4.49

  Basal LH (IU/L)                         0.66                                    0.26                                           2.5                  0.4                  0.309                                          2.85                          2.56

  Peak LH (IU/L)                          23.76                                   7.5                                            6.4                  6.8                  5.5                                            7.1                           5.6

  Thyroid function status                 Euthyroid                               Euthyroid                                      Euthyroid            Euthyroid            Euthyroid                                      Euthyroid                     Euthyroid

  Prolactin (ng/ml)                       6.55                                    8.98                                           10.77                6.66                 22.6                                           7.22                          6.69

  Pelvic USG                              Pubertal                                Prepubertal                                    Prepubertal          Pubertal             \-                                             \-                            \-

  Hypophysis/cranial MR                   N                                       N                                              N                    N                    N                                              N                             N

  Follow up                               3 mo later developed bilaterally T3.\   6-mo follow-up, without treatment, no change   Follow-up (2 mo)     Follow-up (2mo)      6-mo follow-up, without treatment, no change   Without treatment follow-up   6-mo follow-up, without treatment, no change
                                          GnRH analogue treatment was started.                                                                                                                                                                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ADHD, attention deficit hyperactivity disorder; MPH, methylphenidate; E2, estradiol; LH, luteinizing hormone; USG, ultrasonography; MR, magnetic resonance; N, normal cranial MR imaging; GnRH, gonadotropin-releasing hormone.

Normal range of the hormones: for E2, 2--18 pg/ml; for testosterone, 2.3--8 ng/ml; for basal LH, 0.2--5.0 IU/L; for peak LH, 12--80 IU/L.
